FPC
RARE icon

Flax Pond Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Flax Pond Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
56,838
+200
+0.4% +$4.97K 1.32% 29
2026
Q1 		$1.19M Buy
56,638
+400
+0.7% +$9.01K 0.95% 32
2025
Q4 		$1.29M Buy
+56,238
New +$1.85M 0.96% 37

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Flax Pond Capital's RARE Position: Q2 2026 in Review

Flax Pond Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 0.35% in Q2 2026, buying an estimated $4.97K and bringing the position to 56,838 shares worth $1.9M. The position accounts for 1.32% of the portfolio, ranked #29.

Flax Pond Capital first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Flax Pond Capital held 56,838 shares of Ultragenyx Pharmaceutical worth $1.9M as of Q2 2026.
  • Flax Pond Capital bought 200 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.97K.
  • Ultragenyx Pharmaceutical made up 1.32% of Flax Pond Capital's portfolio in Q2 2026, its #29 holding.
  • Flax Pond Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Flax Pond Capital's 13F filing for Q2 2026, filed 13 Aug 2026.